GlassScriptPhysician profile
Cynthia Polo
$514.98
in general payments reported to CMS, 2019-2025
12 companies · $15.01 in 2025
The $15.01 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2021: $43.92 · 2022: $135 · 2023: $18.02 · 2024: $84.91 · 2025: $15.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $126.76 | 2019-2024 | Libtayo, Dupixent |
| Abbvie INC. | $72.64 | 2019-2022 | |
| Amgen INC. | $70.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.51 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.74 | 2019 | |
| Genentech USA, INC. | $28.64 | 2019-2022 | |
| Lilly USA, LLC | $26.05 | 2021-2022 | |
| Aclaris Therapeutics, INC. | $19.95 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.52 | 2021 | |
| Incyte Corporation | $16.85 | 2022 | |
| Galderma Laboratories, L.P. | $15.01 | 2025 | Nemluvio |
| Biofrontera INC. | $9.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Polo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.